AzTrials
AzTrials

Renal FailureVCENCT02627066

Optimizing Cardiovascular Health and Physical Function in Hemodialysis Patients Through Volume Control and Exercise

A study of Renal Failure, run by University of Illinois at Urbana-Champaign at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a 12 month randomized clinical trial in which patients with renal failure undergoing maintenance hemodialysis (MHD) therapy will be placed on a volume reduction protocol that includes a novel low sodium dietary education program mediated by a lifestyle interventionist with significant collaboration from the… Read more about this study

Who is it for?
Ages 20 to 90 years
Conditions the study is for
Renal Failure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
37 participants
Where
1 siteUnited States
Study dates
Dec 2015to Jul 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Any patient with a blood pressure > 130/85, or prescribed at least one anti-hypertensive medication

Who cannot join

  • Patients already below their prescribed dry weights and who are normotensive in the absence of hypertensive medications, and without peripheral edema

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Illinois at Urbana-Champaign

    Urbana, Illinois, 61801

Other trials in United States

About this study

This is a 12 month randomized clinical trial in which patients with renal failure undergoing maintenance hemodialysis (MHD) therapy will be placed on a volume reduction protocol that includes a novel low sodium dietary education program mediated by a lifestyle interventionist with significant collaboration from the existing clinic staff. Participating patients will be randomized to receive: 1) the volume control protocol alone (VC), or 2) the volume control protocol + physical activity and exercise counseling (VCE) from the lifestyle interventionist (LI). A research dietitian (RD), working in collaboration with the existing clinic RD, will develop a program to immerse clinics in a culture of sodium restriction. The research RD will train the LI and other clinic staff (nurses, technicians, etc) to help disseminate this program, modeled after the clinic-wide dissemination approach used in Izmir, Turkey (Dr. Ercan Ok). In addition, the LI will provide exercise and physical activity counseling to the participants randomized to the exercise group, utilizing a SCT-based approach. The Investigators hypothesize that mean arterial pressure will be reduced, and physical function increased, in all patients at 12 months, but the magnitude of these improvements will be greater in the VCE group.

Read the detailed description

Patients with kidney failure require regular hemodialysis (HD) therapy 3-4 days per week to filter their blood and remove excess fluid. However, the dialysis process is inefficient, as it typically does not remove all of the fluid and waste products that accumulate in patients since their last treatment. This accumulation of excess fluid is called volume overload (VO). Chronic VO can have adverse effects on the heart and arteries, primarily by increasing blood pressure, eventually lead to enlargement of the heart and cardiac dysfunction (1-3). Some evidence also suggests that it adversely impacts patient's physical activity levels and function.

Past research has shown that a patient's fluid volume can be controlled using 'volume control' strategies. These strategies involve progressively reducing a patient's post-dialysis body weight by slowly increasing the amount of fluid removed during each dialysis session (e.g., by removing an extra 200-300ml of fluid each session). Patient's dietary sodium intake is simultaneously restricted to control their thirst and to prevent fluid intake and accumulation between their treatments. Stringent volume control has been shown to improve cardiovascular health and reduce mortality (2-3), but is rarely/never practiced in U.S. dialysis clinics. Instead, patients in the U.S. are normally provided blood pressure or other medications to help mitigate the effects of excessive fluid accumulation between sessions. However, there is little evidence that these medications are efficacious, as most have no impact on fluid accumulation per se. Moreover, dietary sodium restriction, a principle component of successful volume reduction strategies, often requires comprehensive changes to an individual's diet due to the pervasive inclusion of salt in the U.S. food supply. Registered dietitians provide the majority of nutrition counseling to HD patients, but they lack the time to provide the level of care needed to sustain patient's dietary changes. As a result, chronic volume overload is a common problem in U.S. dialysis patients, as there are no established protocols for managing this problem other than through pharmacological interventions with no proven efficacy.

The investigators are proposing a multifactorial intervention designed to improve HD patient's cardiovascular health and physical function. The intervention includes a novel volume control protocol that may be combined with exercise training to optimize the benefits of the volume control strategy. HD patients from selected clinics will be randomly assigned to: 1) volume control protocol (VC); or 2) VC + exercise training (VCE). The VC protocol will include 2 primary components: 1) a progressive increase in the amount of fluid removed during a patient's dialysis treatment (ultrafiltration volume) at the discretion of the patient's physician, and 2) a dietary intervention to improve patient's food choices, focused on reducing the intake of fast and processed foods that are high in sodium, as well as phosphorus additives that may also have damaging effects on the heart, arteries, and bone. The dietary intervention will involve training the existing clinic staff to help deliver better and more consistent nutritional messages to their patients, to supplement the work of the existing clinic dietitian.

Patients randomized to exercise group (VCE) will receive the VC intervention in addition to a personalized exercise training and physical activity prescription from a "lifestyle interventionist" (LI). This will include exercise during dialysis treatment, as well as counseling on how to increase physical activity levels outside of the clinic - namely at home or in the community.

The LI will also help deliver the nutritional education component of the VC protocol. As most HD clinics typically employ one or more full time registered dietitians, the LI will work closely with them to support their work. The LI will focus on basic nutrition messages including decreasing the intake of fast and processed foods, ensuring regular meals, and adequate protein intake. This education will be conducted according to the Fresenius Tech Talk model. Short in-services will be held with clinic staff to educate them on general nutrition principles. Staff will be encouraged to incorporate these talking points into patient conversations. Outcomes will be evaluated by the LI at baseline, and after 6 and 12 months. Primary outcomes include mean arterial blood pressure and physical function. Secondary outcomes include: hospitalization rates, cardiovascular function, dialysis compliance, fall incidence, and blood pressure medication prescription.

This study will provide novel information regarding the effects of a novel volume control strategy and exercise training on physical function and cardiovascular health in HD patients. Results from this study will enable nephrologists to make more informed decisions regarding the extent to which this low-cost treatment strategy should be included as a component of the standard care in their clinics. Ultimately, this could lead to greater use of this treatment strategy and result in significant improvements in the health and quality of life of this critically ill patient population.

Conditions
Renal Failure
Being tested
Volume Control, Volume Control + Exercise
Keywords
Exercise, Nutrition, Hemodialysis
Medical subject headings
Renal Insufficiency, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Volume ControlBehavioural

    Persistent reduction in post-dialysis weight and dietary sodium restriction

  • Volume Control + ExerciseBehavioural

    Volume reduction intervention and comprehensive exercise counseling

Study groups in NCT02627066
Study groupRoleWhat they receive
Volume ControlActive comparatorThis group of patients will receive a volume reduction protocol that includes two primary components: 1) persistent ultrafiltration to slowly reduce patient's post-dialysis weight; and 2) persistent dietary education focused on reducing intake of dietary sodium and phosphorus additives
Receives: Behavioral: Volume Control
Volume Control + ExerciseActive comparatorThis group of patients will receive the volume control intervention in addition to intensive counseling to increase their physical activity levels.
Receives: Behavioral: Volume Control + Exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Volume Overload

    Bioelectrical Impedance Determined Extracellular Hydration status

    Measured: 6 months

Secondary outcomes (5)
  1. Blood Pressure

    Systolic and Diastolic blood pressure

    Measured: monthly for 6 months

  2. Blood Pressure Medication use

    Number of blood pressure medications prescribed

    Measured: 0 and 6 months

  3. Stroke Volume

    Stroke volume will be measured under standardized conditions (resting for 5 minutes, before dialysis treatment) utilizing a whole body bioimpedance- based measurement device (NiCAS, inc)

    Measured: 0 and 6 months

  4. Treatment Compliance

    Percentage of missed dialysis sessions per month

    Measured: 0 and 6 months

  5. Dietary sodium intake

    Assessed using USDA 5-pass method, on a dialysis and non-dialysis day

    Measured: 0 and 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Dec 2015 (estimated)
  2. Study startDec 2015
  3. Primary completionNov 2017
  4. Study completionJul 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
37 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02627066
Sponsor's protocol ID
14072
Acronym
VCE
Status last verified
Jul 2018
First submitted
8 Dec 2015
Last updated
2 Aug 2018
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study of Renal Failure, run by University of Illinois at Urbana-Champaign at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Volume Overload (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Aug 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in